Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy
| Author | Kamuran Turker | en |
| Author | Betul Tas | en |
| Author | Murat Ozkaya | en |
| Author | Ebru Tas | en |
| Author | Aysel Caglar | en |
| Author | Umit Seza Tetikkurt | en |
| Issued Date | 2015-03-31 | en |
| Abstract | Introduction: Various types of dermatological manifestations have been reported due to hepatitis C virus (HCV) infection and antiHCV therapy. Some of them have been described during IFN-based therapies. PEG-IFN-α-2a/RBV combination is used as the international standard of treatment for HCV infection for a long time. The combination therapy yields an adverse-event profile similar to standard interferon (IFN) therapy. Some of these adverse effects are rheumatologic, neuropsychiatric and dermatological manifestations including alopecia. Case Presentation: We reported a 43-year-old woman with dystrophic anagen effluvium (DAE), rheumatoid arthritis and Hashimoto thyroiditis, which were developed under the combination therapy for chronic HCV infection. Conclusions: Although some cases of alopecia areata (AA) and telogen effluvium (TE) were reported in literature, no case of DAE associated with PEG-INF-α-2a /RBV combination therapy was reported previously. | en |
| DOI | https://doi.org/10.5812/hepatmon.24804 | en |
| Keyword | Alopecia | en |
| Keyword | Interferon | en |
| Keyword | Therapy | en |
| Keyword | Chronic Hepatitis C | en |
| Publisher | Brieflands | en |
| Title | Dystrophic-Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy | en |
| Type | Case Report | en |